The patent office in India has slapped down an application from Tokyo-based Takeda Pharmaceutical for its single-dose Type 2 diabetes treatment dipeptidyl peptidase 4 (DPP-4) inhibitor.
Switzerland-based Novartis sees Mumbai-based Sun Pharmaceutical Industries meeting its February target start date for sales of generic Gleevec/Glivec (imatinib), putting the Indian drugmaker in the spotlight on the deadline.
The Supreme Court of India will allow a scientist to join the patent case involving Indian drug giant Cipla which had earlier been found to have violated the Roche patent on its Tarceva (erlotinib) cancer drug.
Medicines produced in India for domestic consumption are failing quality tests performed by a government task force set up to investigate poor manufacturing practices.
A recent study in The Lancet showed that India is outperforming other so-called high-burden countries in offering the cheapest access to the World Health Organization-approved Xpert MTB/RIF screening for TB.
Changes in intellectual property (IP) rules in the European Union have Indian drugmakers worried because the new regulations empower EU countries like Belgium to impound Indian-made drugs that are transshipped via the EU to developing countries in Latin America and Africa, according to a report by the Economic Times.
The governments of India and France have agreed to make up for lost time and said this week they remain committed to restarting free trade negotiations between New Delhi and the European Union that have been stalled for the past three years.
U.S. injectables maker Sagent Pharmaceuticals is considering putting itself on the chopping block, and if or when it does, at least 5 Indian drugmakers could come calling.
A slew of Indian drugmakers are in a race to buy U.S.-based Sagent Pharmaceuticals, the Economic Times reports, suggesting a price tag north of $500 million and competition between large generics companies and private equity.
Bangalore-based Indian drugmaker Biocon drew some brickbats from analysts after third-quarter earnings were released because of disappointing progress in sales of biopharma products, prompting management to go into details about plans to grow the business.